Introduction
Recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 is a protein that has been genetically engineered through recombinant DNA technology. This protein is a major structural component of the Coxsackievirus A10 (CA10) virus, which belongs to the family Picornaviridae. The recombinant form of this protein has been extensively studied and has shown promising results in terms of its structure, activity, and potential applications.
Structure of Recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 is a 297 amino acid long protein with a molecular weight of approximately 33 kDa. It has a characteristic icosahedral structure with 60 subunits arranged in a T=1 symmetry. Each subunit consists of four major domains – the N-terminal arm, the core domain, the BC loop, and the C-terminal arm. The core domain is the largest and most conserved region of the protein and is responsible for its structural stability.
Activity of Recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 has been found to have several important activities. One of its main functions is to form the viral capsid, which protects the viral genome and facilitates its entry into host cells. The protein also has a role in viral replication and assembly. Additionally, it has been shown to interact with host cell receptors and trigger immune responses.
Application of Recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 has a wide range of potential applications in the field of medicine and research. Some of the key applications of this protein are discussed below.
Vaccine development
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 has been identified as a potential antigen for the development of a vaccine against CA10 virus. Studies have shown that the protein can induce neutralizing antibodies and provide protection against CA10 infection. This makes it a promising candidate for inclusion in a multivalent enterovirus vaccine.
Detection of CA10 infection
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 has also been used in diagnostic assays for the detection of CA10 infection. The protein can be used as an antigen in serological tests to detect the presence of CA10-specific antibodies in patient samples. This can help in the early and accurate diagnosis of CA10 infection.
Research tool
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 has been used as a research tool to study the structure and function of the CA10 virus. Its recombinant form allows for easier purification and manipulation, making it a valuable tool for studying viral replication, assembly, and host-virus interactions.
Therapeutic agent
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 has also shown potential as a therapeutic agent for the treatment of CA10 infection. Studies have shown that the protein can inhibit viral replication and reduce viral load in infected cells. This makes it a potential candidate for the development of antiviral drugs against CA10.
Target for drug development
The recombinant Coxsackievirus A10/CA10 VP1/Capsid protein VP1 has been identified as a potential target for the development of antiviral drugs against CA10. The protein plays a crucial role in viral replication and assembly, making
There are no reviews yet.